First AD

Second AD

Daniel J. George, MD, is the Eleanor Easley Distinguished Professor, a professor of medicine, a professor in urology, and a professor in surgery at the Duke University School of Medicine and a member of the Duke Cancer Institute.

Matthew Smith, MD, PhD, is the Claire and John Bertucci Endowed Chair in Genitourinary Cancers and director of the Genitourinary Malignancies Program at Massachusetts General Hospital, as well as a professor of medicine at Harvard Medical School.

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.

Findings From a Real-World Analysis of ARPIs in Nonmetastatic CRPC

Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 